Hostname: page-component-cb9f654ff-p5m67 Total loading time: 0 Render date: 2025-08-11T15:09:41.145Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparing the Clinical Trial Characteristics of Industry-Funded Trials and Non Industry-Funded Trials

Published online by Cambridge University Press:  16 December 2024

Emily Hughes ,
Tamara Van Bakel ,
Ashley Raudanskis ,
Prachi Ray ,
Benazir Hodzic-Santor ,
Ushma Purohit ,
Chana A. Sacks  and
Michael Fralick
Emily Hughes
Affiliation:
SINAI HEALTH SYSTEM, DIVISION OF GENERAL INTERNAL MEDICINE, TORONTO, ONTARIO, CANADA
Tamara Van Bakel
Affiliation:
LUNENFELD-TANENBAUM RESEARCH INSTITUTE, SINAI HEALTH SYSTEM, TORONTO, ONTARIO, CANADA
Ashley Raudanskis
Affiliation:
SINAI HEALTH SYSTEM, DIVISION OF GENERAL INTERNAL MEDICINE, TORONTO, ONTARIO, CANADA
Prachi Ray
Affiliation:
SINAI HEALTH SYSTEM, DIVISION OF GENERAL INTERNAL MEDICINE, TORONTO, ONTARIO, CANADA
Benazir Hodzic-Santor
Affiliation:
SINAI HEALTH SYSTEM, DIVISION OF GENERAL INTERNAL MEDICINE, TORONTO, ONTARIO, CANADA
Ushma Purohit
Affiliation:
SINAI HEALTH SYSTEM, DIVISION OF GENERAL INTERNAL MEDICINE, TORONTO, ONTARIO, CANADA
Chana A. Sacks
Affiliation:
DIVISION OF GENERAL INTERNAL MEDICINE AND MONGAN INSTITUTE, MASSACHUSETTS GENERAL HOSPITAL, HARVARD MEDICAL SCHOOL, BOSTON, USA
Michael Fralick
Affiliation:
SINAI HEALTH SYSTEM, DIVISION OF GENERAL INTERNAL MEDICINE, TORONTO, ONTARIO, CANADA LUNENFELD-TANENBAUM RESEARCH INSTITUTE, SINAI HEALTH SYSTEM, TORONTO, ONTARIO, CANADA
Get access Rights & Permissions [Opens in a new window]

Abstract

We compared study characteristics of randomized controlled trials funded by industry (N=697) to those not funded by industry (N=835). RCTs published in high-impact journals are more likely to be blinded, more likely to include a placebo, and more likely to post trial results on ClinicalTrials.gov. Our findings emphasize the importance of evaluating the quality of an RCT based on its methodological rigor, not its funder type.

Keywords

Randomized Controlled TrialsFunderTrial CharacteristicsPharmaceuticalIndustryNatural Language Processing

Information

Type
Independent Articles
Information
Journal of Law, Medicine & Ethics , Volume 52 , Issue 3: Emerging Technologies to Stop Biological Time: The Ethical, Legal & Policy Challenges of Advanced Biopreservation , Fall 2024 , pp. 693 - 700
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

The Committee of the Medical Research Council, “Streptomycin Treatment of Pulmonary Tuberculosis: A Medical Research Council Investigation,” British Medical Journal 2, no. 4582 (1948): 769–782.CrossRefGoogle Scholar
Bhatt, A., “Evolution of Clinical Research: A History Before and Beyond James Lind,” Perspectives in Clinical Research 1, no. 1 (2010): 6–10.CrossRefGoogle ScholarPubMed
Kendall, J.M., “Designing a Research Project: Randomized Controlled Trials and their Principles,” Emergency Medicine Journal 20, no. 2 (2003): 164–168; H.O. Stolberg, G. Norman, and I. Trop, “Randomized Controlled Trials,” American Journal of Roentgenology 183, no. 6 (2004): 1539–1544.CrossRefGoogle ScholarPubMed
Suissa, S., “Immortal Time Bias in Pharmaco-Epidemiology,” American Journal of Epidemiology 167, no. 4 (2008): 492–499.CrossRefGoogle ScholarPubMed
See Kendall, supra note 3.Google Scholar
Sertkaya, A. et al., “Key Cost Drivers of Pharmaceutical Clinical Trials in the United States,” Clinical Trials 13, no. 2 (2016): 117–126.CrossRefGoogle ScholarPubMed
Chopra, S.S., “Industry Funding of Clinical Trials: Benefit or Bias?” Journal of the American Medical Association 290, no. 1 (2003): 113–114.Google ScholarPubMed
Bodenheimer, T., “Uneasy Alliance — Clinical Investigators and the Pharmaceutical Industry,” New England Journal of Medicine 342, no. 20 (2000): 1539–1544.CrossRefGoogle ScholarPubMed
Keller, M.B. et al., “Efficacy of Paroxetine in the Treatment of Adolescent Major Depression: A Randomized, Controlled Trial,” Journal of the American Academy of Child & Adolescent Psychiatry 40, no. 7 (2001): 762–772.CrossRefGoogle ScholarPubMed
Le Noury, J. et al., “Restoring Study 329: Efficacy and Harms of Paroxetine and Imipramine in Treatment of Major Depression in Adolescence,” BMJ 351 (2015): h4320.CrossRefGoogle ScholarPubMed
Kesselheim, A.S. et al., “A Randomized Study of How Physicians Interpret Research Funding Disclosures,” New England Journal of Medicine 367, no. 12 (2012): 1119–1127.CrossRefGoogle ScholarPubMed
Fralick, M. et al., “Understanding When Real World Data Can Be Used to Replicate A Clinical Trial: A Cross-Sectional Study of Medications Approved in 2011,” Pharmacoepidemiology and Drug Safety 29, no. 10 (2020): 1273–1278.Google ScholarPubMed
Yang, X. et al., “Clinical Concept Extraction Using Transformers,” Journal of the American Medical Informatics Association 27, no. 12 (2020): 1935–1942.CrossRefGoogle ScholarPubMed
J. Devlin et al., “BERT: Pre-training of Deep Bidirectional Transformers for Language Understanding,” abstract from presentation at the 2019 Annual Conference of the North American Chapter of the Association for Computational Linguistics, printed in Proceedings of the 2019 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies 1 (2019): 4171–4186.Google Scholar
See Chopra, supra note 7; Gelijns, A.C. and Thier, S.O., “Medical Innovation and Institutional Interdependence: Rethinking University-Industry Connections,” Journal of the American Medical Association 287, no. 1 (2002): 72–77.CrossRefGoogle ScholarPubMed
DeVito, N.J., Bacon, S., and Goldacre, B., “Compliance with Legal Requirement to Report Clinical Trial Results on ClinicalTrials.gov: A Cohort Study,” Lancet 395, no. 10221 (2020): 361–369.CrossRefGoogle ScholarPubMed
Anderson, M.L. et al., “Compliance with Results Reporting at ClinicalTrials.gov,” New England Journal of Medicine 372, no. 11 (2015): 1031–1039.CrossRefGoogle ScholarPubMed
Ross, J.S. et al., “Trial Publication After Registration in ClinicalTrials.gov: A Cross-Sectional Analysis,” PLOS Medicine 6, no. 9 (2009): e1000144; B. Goldacre, “Trial Sans Error: How Pharma-Funded Research Cherry-Picks Positive Results [Excerpt],” Scientific American, February 13, 2013, available at <https://www.scientificamerican.com/article/trial-sans-error-how-pharma-funded-research-cherry-picks-positive-results/> (last visited September 11, 2024); B. Djulbegovic et al., “The Uncertainty Principle and Industry-Sponsored Research,” Lancet 356, no. 9230 (2000): 635–638; R. Collier, “Is Withholding Clinical Trial Results ‘Research Misconduct’?” Canadian Medical Association Journal 187, no. 10 (2015): 724; D. Eyding et al., “Reboxetine for Acute Treatment of Major Depression: Systematic Review and Meta-Analysis of Published and Unpublished Placebo and Selective Serotonin Reuptake Inhibitor Controlled Trials,” BMJ 341 (2010): c4737.CrossRefGoogle ScholarPubMed
See Le Noury, supra note 10.Google Scholar
Gupta, Y.K., Meenu, M., and Mohan, P., “The Tamiflu Fiasco and Lessons Learnt,” Indian Journal of Pharmacology 47, no. 1 (2015): 11–16.CrossRefGoogle ScholarPubMed
Jefferson, T. et al., “Neuraminidase Inhibitors for Preventing and Treating Influenza in Adults and Children,” Cochrane Database of Systematic Reviews 2014, no. 4 (2014): CD008965.Google Scholar